Literature DB >> 7853586

Complications of post-chemotherapy retroperitoneal lymph node dissection.

J Baniel1, R S Foster, R G Rowland, R Bihrle, J P Donohue.   

Abstract

The surgical morbidity rate of 603 patients who underwent lymphadenectomy after primary chemotherapy for clinical stages II and III testis cancer from 1982 to 1992 was reviewed. There were 144 complications in 125 patients (20.7%). The majority of patients (93%) had a tumor volume of greater than 5 cm. Five patients died 3 to 47 days postoperatively, for an operative mortality rate of 0.8%. Pulmonary complications were the most frequent cause of severe morbidity: 6 patients had the adult respiratory distress syndrome and 5 needed prolonged ventilation. The underlying cause was a combination of bleomycin induced pulmonary toxicity, and large volume retroperitoneal and pulmonary disease resected in these patients. Limiting inspired oxygen concentration and perioperative volume replacement are imperative to minimize bleomycin related pulmonary morbidity. Additional procedures, such as nephrectomy and colectomy, did not add to the morbidity rate. Among patients undergoing concomitant venacavectomy there was a higher occurrence of postoperative chylous ascites. Most of the other complications (gastrointestinal, lymphatic, neurological and renal) were temporary and treated conservatively. Perioperative management of the post-chemotherapy testis cancer patient is different from that of the patient undergoing primary retroperitoneal lymphadenectomy. The latter operation is usually performed in physically fit patients and the surgical template of dissection is of a smaller scale. Thus, the complications in this group are minor and without mortality. Specific technical considerations and difficulties are common to post-chemotherapy patients. Factors, such as large volume of disease, post-chemotherapy desmoplastic reaction and extensive retroperitoneal dissection, make these patients more prone to have complications. Decreased pulmonary, renal and nutritional reserves add to the surgical morbidity. Knowledge of possible pitfalls and their causes can avoid unnecessary operative complications.

Entities:  

Mesh:

Year:  1995        PMID: 7853586

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  30 in total

Review 1.  Secondary surgery in germ cell tumors--when and how extensively should it be performed?

Authors:  Richard S Foster; Stephen Beck; Richard Bihrle
Journal:  World J Urol       Date:  2004-03-30       Impact factor: 4.226

2.  [Retroperitoneal lymphadenectomy - pro robotic].

Authors:  P Albers
Journal:  Urologe A       Date:  2012-05       Impact factor: 0.639

3.  Canadian consensus guidelines for the management of testicular germ cell cancer.

Authors:  Lori Wood; Christian Kollmannsberger; Michael Jewett; Peter Chung; Sebastian Hotte; Martin O'Malley; Joan Sweet; Lynn Anson-Cartwright; Eric Winquist; Scott North; Scott Tyldesley; Jeremy Sturgeon; Mary Gospodarowicz; Roanne Segal; Tina Cheng; Peter Venner; Malcolm Moore; Peter Albers; Robert Huddart; Craig Nichols; Padraig Warde
Journal:  Can Urol Assoc J       Date:  2010-04       Impact factor: 1.862

4.  The internal anatomy of the inferior vena cava with specific emphasis on the entrance of the renal, gonadal and lumbar veins.

Authors:  Kathleen Bubb; Maira du Plessis; Robert Hage; R Shane Tubbs; Marios Loukas
Journal:  Surg Radiol Anat       Date:  2015-08-07       Impact factor: 1.246

5.  [Testicular tumor--yesterday--today--tomorrow].

Authors:  S Krege; C Wittekind; R Souchon; F Honecker; C Bokemeyer; P Albers; J Gschwend; H Rübben
Journal:  Urologe A       Date:  2006-09       Impact factor: 0.639

Review 6.  Reducing morbidity of pelvic and retroperitoneal lymphadenectomy.

Authors:  Mark W Ball; Michael A Gorin; Mohamad E Allaf
Journal:  Curr Urol Rep       Date:  2013-10       Impact factor: 3.092

Review 7.  Critical evaluation of modified templates and current trends in retroperitoneal lymph node dissection.

Authors:  Shane Pearce; Zoe Steinberg; Scott Eggener
Journal:  Curr Urol Rep       Date:  2013-10       Impact factor: 3.092

8.  [Management of complications after residual tumor resection for metastatic testicular cancer].

Authors:  A Lusch; M Zaum; C Winter; P Albers
Journal:  Urologe A       Date:  2014-07       Impact factor: 0.639

Review 9.  Residual tumor resection (RTR).

Authors:  A Lusch; P Albers
Journal:  World J Urol       Date:  2016-12-21       Impact factor: 4.226

10.  Management of good-risk metastatic nonseminomatous germ cell tumors of the testis: current concepts and controversies.

Authors:  Gautam Jayram; Russell Z Szmulewitz; Scott E Eggener
Journal:  Indian J Urol       Date:  2010 Jan-Mar
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.